{"id":48757,"date":"2022-09-23T18:02:29","date_gmt":"2022-09-23T16:02:29","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/massive-bio-continues-to-grow-in-europe\/"},"modified":"2022-09-23T18:02:29","modified_gmt":"2022-09-23T16:02:29","slug":"massive-bio-continues-to-grow-in-europe","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/massive-bio-continues-to-grow-in-europe\/","title":{"rendered":"Massive Bio Continues to Grow in Europe"},"content":{"rendered":"
\n

\nThree senior executives join Massive Bio, which is expanding its operations in Europe with Series B investments<\/b>\n<\/p>\n

<\/a><\/p>\n

NEW YORK–(BUSINESS WIRE)–#AI<\/a>—Massive Bio<\/a><\/i>, which uses its proprietary artificial intelligence-based platform to match cancer patients to clinical trials regardless of where they live or their financial circumstances, is expanding its operations in Europe. With support from Series B investments received in the first half of this year, Massive Bio announced the hiring of three new team members who will help expand the company’s global operations, intensify its marketing activities, develop new data sets and products, and expand its M&A efforts. The new recruits are Toygun Onaran<\/a>,<\/i> <\/i>who will serve as Head of Strategy<\/i>; Mert Sar\u0131<\/a>, <\/i>who will be Regional Manager<\/i>; and Sinan F\u0131nd\u0131k<\/a><\/i>, who comes on board as Clinical Research and Data Manager<\/i>.\n<\/p>\n

\nMassive Bio’s expanding presence in Europe will allow the company to continue its mission of ensuring that all cancer patients receive treatment under fair and favorable conditions, said \u00c7a\u011flar Demirba\u011f<\/a><\/i>,<\/i> Director of International Partnerships, which manages the company\u2019s operations outside of the United States, adding that \u201cthere are about 4 million patients diagnosed with cancer annually in Europe. With the steps we have taken in the last two years, we have been ensuring that thousands of cancer patients in Spain, Italy, France, Germany, Romania, Poland, and Greece are matched to appropriate clinical trials. This is also enabling that these patients receive the best treatment free of charge.\u201d\n<\/p>\n

\n\u201cThe current changes we are making today will help us better reach and support more cancer patients in the future,” added Erkan Terzi<\/a><\/i>, <\/i>Massive Bio’s Vice President of Global Marketing. Terzi said, “At Massive Bio, we work on three continents in 32 different functional areas in our marketing efforts. Our recent updates, newsletters, infographics, new video production, digital-asset improvements, content writing, and advertising management continue to help us create a more comprehensive and effective patient-use case. The technologies we use and the integrated studies we create with different units enable us to work more effectively in the business focus.\u201d\n<\/p>\n

\nAbout Massive Bio<\/i><\/b>\n<\/p>\n

\nFounded in New York City in 2015, Massive Bio aims to provide access to clinical trials for cancer patients worldwide, regardless of where they live or their financial circumstances.<\/i>\n<\/p>\n

\nYou can reach Massive Bio via 100KSINGULARITY@massivebio.com<\/a>, Twitter<\/a>, LinkedIn<\/a>, and Facebook<\/a>.<\/i>\n<\/p>\n

Contacts<\/b> <\/p>\n

\nMedia<\/b>
Merve Sahin
\n
msahin@massivebio.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Three senior executives join Massive Bio, which is expanding its operations in Europe with Series B investments NEW YORK–(BUSINESS WIRE)–#AI—Massive Bio, which uses its proprietary artificial intelligence-based platform to match cancer patients to clinical trials regardless of where they live or their financial circumstances, is expanding its operations in Europe. With support from Series B … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-48757","6":"format-standard","7":"category-industry"},"yoast_head":"\nMassive Bio Continues to Grow in Europe - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/massive-bio-continues-to-grow-in-europe\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Massive Bio Continues to Grow in Europe - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Three senior executives join Massive Bio, which is expanding its operations in Europe with Series B investments NEW YORK–(BUSINESS WIRE)–#AI—Massive Bio, which uses its proprietary artificial intelligence-based platform to match cancer patients to clinical trials regardless of where they live or their financial circumstances, is expanding its operations in Europe. With support from Series B ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/massive-bio-continues-to-grow-in-europe\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-23T16:02:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220923005244\/en\/1581196\/21\/Operation-Europe-Project.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/massive-bio-continues-to-grow-in-europe\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/massive-bio-continues-to-grow-in-europe\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Massive Bio Continues to Grow in Europe\",\"datePublished\":\"2022-09-23T16:02:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/massive-bio-continues-to-grow-in-europe\\\/\"},\"wordCount\":405,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/massive-bio-continues-to-grow-in-europe\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220923005244\\\/en\\\/1581196\\\/21\\\/Operation-Europe-Project.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/massive-bio-continues-to-grow-in-europe\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/massive-bio-continues-to-grow-in-europe\\\/\",\"name\":\"Massive Bio Continues to Grow in Europe - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/massive-bio-continues-to-grow-in-europe\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/massive-bio-continues-to-grow-in-europe\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220923005244\\\/en\\\/1581196\\\/21\\\/Operation-Europe-Project.jpg\",\"datePublished\":\"2022-09-23T16:02:29+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/massive-bio-continues-to-grow-in-europe\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/massive-bio-continues-to-grow-in-europe\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/massive-bio-continues-to-grow-in-europe\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220923005244\\\/en\\\/1581196\\\/21\\\/Operation-Europe-Project.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220923005244\\\/en\\\/1581196\\\/21\\\/Operation-Europe-Project.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/massive-bio-continues-to-grow-in-europe\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Massive Bio Continues to Grow in Europe\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Massive Bio Continues to Grow in Europe - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/massive-bio-continues-to-grow-in-europe\/","og_locale":"en_US","og_type":"article","og_title":"Massive Bio Continues to Grow in Europe - Pharma Trend","og_description":"Three senior executives join Massive Bio, which is expanding its operations in Europe with Series B investments NEW YORK–(BUSINESS WIRE)–#AI—Massive Bio, which uses its proprietary artificial intelligence-based platform to match cancer patients to clinical trials regardless of where they live or their financial circumstances, is expanding its operations in Europe. With support from Series B ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/massive-bio-continues-to-grow-in-europe\/","og_site_name":"Pharma Trend","article_published_time":"2022-09-23T16:02:29+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220923005244\/en\/1581196\/21\/Operation-Europe-Project.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/massive-bio-continues-to-grow-in-europe\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/massive-bio-continues-to-grow-in-europe\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Massive Bio Continues to Grow in Europe","datePublished":"2022-09-23T16:02:29+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/massive-bio-continues-to-grow-in-europe\/"},"wordCount":405,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/massive-bio-continues-to-grow-in-europe\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220923005244\/en\/1581196\/21\/Operation-Europe-Project.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/massive-bio-continues-to-grow-in-europe\/","url":"https:\/\/pharma-trend.com\/en\/massive-bio-continues-to-grow-in-europe\/","name":"Massive Bio Continues to Grow in Europe - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/massive-bio-continues-to-grow-in-europe\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/massive-bio-continues-to-grow-in-europe\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220923005244\/en\/1581196\/21\/Operation-Europe-Project.jpg","datePublished":"2022-09-23T16:02:29+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/massive-bio-continues-to-grow-in-europe\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/massive-bio-continues-to-grow-in-europe\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/massive-bio-continues-to-grow-in-europe\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220923005244\/en\/1581196\/21\/Operation-Europe-Project.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220923005244\/en\/1581196\/21\/Operation-Europe-Project.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/massive-bio-continues-to-grow-in-europe\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Massive Bio Continues to Grow in Europe"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/48757","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=48757"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/48757\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=48757"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=48757"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=48757"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}